Captrust Financial Advisors Increases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Captrust Financial Advisors lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.1% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 1,680,699 shares of the biopharmaceutical company’s stock after purchasing an additional 49,776 shares during the period. Captrust Financial Advisors’ holdings in Gilead Sciences were worth $140,910,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. nVerses Capital LLC purchased a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $25,000. Valued Wealth Advisors LLC raised its holdings in Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares during the last quarter. CarsonAllaria Wealth Management Ltd. boosted its position in Gilead Sciences by 198.3% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 238 shares in the last quarter. Strategic Investment Solutions Inc. IL acquired a new stake in Gilead Sciences in the second quarter valued at $33,000. Finally, Cedar Wealth Management LLC increased its position in shares of Gilead Sciences by 51.6% in the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 160 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the transaction, the director now owns 8,920 shares in the company, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the transaction, the insider now owns 99,599 shares in the company, valued at $9,113,308.50. The trade was a 20.44 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 63,735 shares of company stock worth $5,589,030. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD opened at $92.41 on Friday. The firm has a market capitalization of $115.17 billion, a PE ratio of 1,026.78, a P/E/G ratio of 2.87 and a beta of 0.17. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The business has a 50-day moving average of $88.08 and a two-hundred day moving average of $77.52.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Gilead Sciences’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter last year, the firm posted $2.29 earnings per share. As a group, research analysts forecast that Gilead Sciences, Inc. will post 4.37 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be issued a dividend of $0.77 per share. The ex-dividend date is Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.33%. Gilead Sciences’s payout ratio is 3,422.22%.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Sanford C. Bernstein started coverage on shares of Gilead Sciences in a research report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price objective on the stock. Leerink Partners raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their price target for the company from $74.00 to $96.00 in a report on Monday, October 21st. Citigroup assumed coverage on shares of Gilead Sciences in a research report on Thursday, November 14th. They issued a “buy” rating and a $125.00 price target on the stock. Mizuho lifted their price objective on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Finally, Wells Fargo & Company increased their target price on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Twelve investment analysts have rated the stock with a hold rating, eleven have given a buy rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $95.41.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.